HHS
Harte Hanks, Inc.
There isn't enough reported data to score HHS yet.
NBIS
Nebius Group N.V.
There isn't enough reported data to score NBIS yet.
HHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
HHS's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
NBIS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Healthy |
NBIS's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
HHS PE Valuation
HHS has no meaningful PE right now: it lost money over the past year.
NBIS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 68x | $22.45 | -83% |
| Fair | 114x | $37.67 | -71% |
| Current | 390x | $129 | — |
| Expensive | 666x | $220 | +71% |
Historical ranges are pointers, not guarantees.
NBIS's PE is 390x, but its earnings don't support one, so it isn't a reliable read right now.
HHS Forward outlook
There aren't enough analyst estimates for HHS to show an outlook.
NBIS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NBIS's revenue to grow and its profitability to improve, with its earnings holding steady. However, they disagree widely on these estimates.
HHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.76 | -$0.37 |
| Q1 2026 | -$0.14 | +$4.04 |
| Q4 2025 | -$0.11 | +$4.04 |
| Q3 2025 | -$0.72 | +$3.38 |
| Q2 2025 | -$0.39 | +$3.65 |
| Q1 2025 | -$4.18 | -$4.06 |
| Q4 2024 | -$4.15 | -$3.94 |
| Q3 2024 | -$4.10 | -234% |
HHS is still losing money, but far less than before: $0.76 per share over the past year, against $4.27 at its worst in late 2019.
NBIS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.33 | +$2.61 |
| Q4 2024 | -$2.28 | -456% |
| Q4 2023 | $0.64 | -36% |
| Q4 2022 | $1.00 | +$1.49 |
| Q4 2021 | -$0.49 | -156% |
| Q4 2020 | $0.87 | +89% |
| Q4 2019 | $0.46 | -73% |
| Q4 2018 | $1.71 | +434% |
NBIS has the edge over HHS in the latest year-over-year earnings comparison.
HHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $38M | -1.7% |
| Q1 2026 | $37.3M | -10% |
| Q4 2025 | $39.9M | -15% |
| Q3 2025 | $39.5M | -17% |
| Q2 2025 | $38.6M | -14% |
| Q1 2025 | $41.6M | -8.6% |
| Q4 2024 | $47.1M | -4.8% |
| Q3 2024 | $47.6M | +1.1% |
HHS has the edge over NBIS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -12% | -12 points |
| Q1 2026 | -2.1% | -2 points |
| Q4 2025 | -0.3% | +3 points |
| Q3 2025 | 1.3% | -2.7 points |
| Q2 2025 | 0.1% | -3 points |
| Q1 2025 | -0.1% | -0.9 points |
| Q4 2024 | -3.3% | +1.3 points |
| Q3 2024 | 4% | -2.2 points |
HHS's operating margin was −12% last quarter, down 12 points from the same quarter a year ago, near the bottom of its range since 2019.
NBIS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $9.7B | +53% |
| Q4 2022 | $6.3B | +46% |
| Q4 2021 | $4.3B | +63% |
| Q4 2020 | $2.6B | +24% |
| Q4 2019 | $2.1B | +37% |
| Q4 2018 | $1.5B | +36% |
| Q4 2017 | $1.1B | +24% |
| Q4 2016 | $917M | +27% |
NBIS's revenue is growing: $530M last quarter, down 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -115% | -112 points |
| Q4 2023 | 3.6% | -11 points |
| Q4 2022 | 2.5% | -14 points |
| Q4 2021 | -3.7% | -18 points |
| Q4 2020 | 7.4% | -9.5 points |
| Q4 2019 | 14% | -2 points |
| Q4 2018 | 16% | -14 points |
| Q4 2017 | 14% | -19 points |
NBIS's operating margin was −115% last quarter, down 123 points from the same quarter a year ago, near the bottom of its range since 2011.
HHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$3M |
| Q1 2026 | -$922K | +$1K |
| Q4 2025 | -$686K | -120% |
| Q3 2025 | $2.2M | +$7M |
| Q2 2025 | -$5.1M | -648% |
| Q1 2025 | -$923K | +$5.3M |
| Q4 2024 | $3.4M | +13% |
| Q3 2024 | -$4.9M | -474% |
HHS has burned cash in six of the last eight quarters: −$1M over the past year, against −$7M the year before.
NBIS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$3.7B | -$3.1B |
| Q4 2024 | -$562.1M | -$316.2M |
| Q4 2023 | -$245.9M | -$138.9M |
| Q4 2022 | -$107M | +$319.7M |
| Q4 2021 | -$426.7M | -539% |
| Q4 2020 | $97.3M | -66% |
| Q4 2019 | $287.9M | +$289.2M |
| Q4 2018 | -$1.3M | -101% |
NBIS has burned cash in six of the last eight quarters: −$4.6B over the past year, against −$43M the year before.
HHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +15K shares |
| 1 year | +0.7% | +49K shares |
| 3 years | -1% | -74K shares |
| 5 years | +3.3% | +238K shares |
| Available history | +18% | +1.1M shares |
HHS has 7M diluted shares, up 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $491,000 |
NBIS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -12% | -33.3M shares |
| 1 year | -32% | -115M shares |
| 3 years | -26% | -86.9M shares |
NBIS has the edge over HHS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | $10M |
| Q4 2021 | $84.1M |
| Q4 2020 | $122.8M |
| Q4 2019 | $17.2M |
| Q4 2018 | $121.8M |
| Q4 2014 | $101.7M |
| Q4 2013 | $102.9M |
HHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.5x | Net Cash |
| Q3 2024 | -1.1x | Net Cash |
| Q2 2024 | -1.7x | Net Cash |
HHS has more cash than debt.
NBIS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 0.7x | Very low |
| Q4 2022 | -0.7x | Net Cash |
NBIS's net debt is less than a year of its operating earnings (EBITDA).
HHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 72.7 | Neutral |
HHS's weekly RSI is 57 (neutral) and its Stochastic is 73 (neutral).
NBIS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 8.3 | Oversold |
NBIS's weekly RSI is 38 (neutral) and its Stochastic is 8 (oversold).
HHS PE vs Communication Services Sector
| Metric | HHS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 16x | — |
HHS has no meaningful PE right now: it lost money over the past year.
NBIS PE vs Communication Services Sector
| Metric | NBIS | Sector median | Relative |
|---|---|---|---|
| PE | 390x | 16x | 2,264% above |
| PE % | 62 | 24 | 38 pts above |
NBIS is trading at 390x earnings, a 2264% premium to the Communication Services sector's median of 16x, though its earnings don't support one.
HHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.21 | 4.3% below |
| 20 week MA | $3.66 | 10% above |
| 50 week MA | $3.14 | 28% above |
| 100 week MA | $3.70 | 8.9% above |
| 200 week MA | $5.54 | 27% below |
HHS has stronger trend alignment. HHS is above 3 of 5 weekly averages versus NBIS above 1 of 4.
NBIS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $179.7 | 28% below |
| 20 week MA | $199.9 | 36% below |
| 50 week MA | $163.5 | 21% below |
| 100 week MA | $110.0 | 17% above |
NBIS has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 17% above its 100-week average.
HHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.46 | $2.55 | -26% |
| 2021 | $2.55 | $8.17 | +220% |
| 2022 | $8.17 | $11.5 | +41% |
| 2023 | $11.5 | $6.79 | -41% |
| 2024 | $6.79 | $5.38 | -21% |
| 2025 | $5.38 | $3.32 | -38% |
| 2026 YTD | $3.32 | $4.03 | +21% |
HHS has finished three years in a row lower, and it's up 21% so far in 2026.
NBIS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $19.6 | $27.3 | +40% |
| 2025 | $27.3 | $87.6 | +221% |
| 2026 YTD | $87.6 | $128.6 | +47% |
NBIS has the edge over HHS on returns for 2026, with the stronger performance.